Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886768 | 0.92 | HPGD (0.47) | HPGDMAPK14CYP3A4LMNAHTT | |
| SCHEMBL5886732 | 0.91 | MAPK14 (0.48) | MAPK14CYP3A4LMNAHTTMMP13 | |
| SCHEMBL5887065 | 0.90 | HTT (0.45) | HPGDMAPK14CYP3A4MAPK8LMNA | |
| SCHEMBL5886848 | 0.90 | CCR1 (0.43) | MAPK14CYP3A4MAPK8LMNAMMP13 | |
| SCHEMBL5887357 | 0.89 | MAPK14 (0.47) | HPGDMAPK14CYP3A4MAPK8LMNA | |
| SCHEMBL5886842 | 0.87 | MET (0.47) | SMN1; SMN2TP53MAPTRXFP1KMT2A | |
| SCHEMBL5886839 | 0.87 | MAPK14 (0.51) | MAPK14CYP3A4LMNAHTTMMP13 | |
| SCHEMBL5887029 | 0.84 | MAPK14 (0.48) | MAPK14CYP3A4LMNAHTTMMP13 | |
| SCHEMBL5887133 | 0.84 | SMN1; SMN2 (0.40) | HPGDMAPK14CYP3A4MAPK8LMNA | |
| SCHEMBL5887053 | 0.84 | MAPK14 (0.47) | MAPK14CYP3A4MAPK8LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | HPGD 1371/4885MAPK14 1051/4885CYP3A4 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.